S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   340.69 (-3.57%)
AAPL   159.78 (-1.14%)
MSFT   274.18 (-7.49%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   90.99 (-6.11%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.39 (+1.65%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   340.69 (-3.57%)
AAPL   159.78 (-1.14%)
MSFT   274.18 (-7.49%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   90.99 (-6.11%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.39 (+1.65%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   340.69 (-3.57%)
AAPL   159.78 (-1.14%)
MSFT   274.18 (-7.49%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   90.99 (-6.11%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.39 (+1.65%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   340.69 (-3.57%)
AAPL   159.78 (-1.14%)
MSFT   274.18 (-7.49%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   90.99 (-6.11%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.39 (+1.65%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:ANIP

ANI Pharmaceuticals Stock Competitors

$41.34
-0.27 (-0.65%)
(As of 01/25/2022 04:30 PM ET)
Add
Compare
Today's Range
$40.13
$41.58
50-Day Range
$39.55
$50.90
52-Week Range
$26.10
$60.23
Volume
91,118 shs
Average Volume
81,401 shs
Market Capitalization
$588.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.21

ANI Pharmaceuticals (NASDAQ:ANIP) Vs. SAGE, RCUS, IMAB, AUPH, TGTX, OPK, EQRX, NKTR, CORT, and HRMY

Should you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include Sage Therapeutics (SAGE), Arcus Biosciences (RCUS), I-Mab (IMAB), Aurinia Pharmaceuticals (AUPH), TG Therapeutics (TGTX), OPKO Health (OPK), EQRx (EQRX), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical preparations" industry.

ANI Pharmaceuticals vs.

ANI Pharmaceuticals (NASDAQ:ANIP) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.

ANI Pharmaceuticals received 245 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 66.29% of users gave ANI Pharmaceuticals an outperform vote while only 66.12% of users gave Arcus Biosciences an outperform vote.

CompanyUnderperformOutperform
ANI PharmaceuticalsOutperform Votes
407
66.29%
Underperform Votes
207
33.71%
Arcus BiosciencesOutperform Votes
162
66.12%
Underperform Votes
83
33.88%

ANI Pharmaceuticals has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.

ANI Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANI Pharmaceuticals$208.48 million2.82-$22.55 million-$1.83-22.59
Arcus Biosciences$77.52 million28.03-$122.86 million-$4.10-7.54

ANI Pharmaceuticals has a net margin of -10.40% compared to Arcus Biosciences' net margin of -735.12%. ANI Pharmaceuticals' return on equity of 17.80% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals -10.40% 17.80% 7.43%
Arcus Biosciences -735.12% -48.12% -32.32%

ANI Pharmaceuticals presently has a consensus price target of $67.50, suggesting a potential upside of 63.64%. Arcus Biosciences has a consensus price target of $62.33, suggesting a potential upside of 101.53%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than ANI Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Arcus Biosciences
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of -0.01 beat ANI Pharmaceuticals' score of -0.05 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ANI Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcus Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

51.3% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.9% of Arcus Biosciences shares are owned by institutional investors. 23.5% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

ANI Pharmaceuticals beats Arcus Biosciences on 11 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANI Pharmaceuticals (NASDAQ:ANIP) vs. Its Competitors

TypeANI PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$588.72M$5.59B$4.53B$6.74B
Dividend YieldN/A2.55%2.06%2.96%
P/E Ratio-22.5913.2216.1818.40
Price / Sales2.82482.565,653.19229.68
Price / Cash6.55162.3360.9368.47
Price / Book2.618.387.408.76
Net Income-$22.55M$98.52M$98.30M$156.36M
7 Day Performance-1.41%-4.27%-4.55%-4.47%
1 Month Performance-18.78%-19.19%-14.95%-11.46%
1 Year Performance28.62%-34.47%-23.16%-9.27%

ANI Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SAGE
Sage Therapeutics
2.6531 of 5 stars
$39.32
-0.9%
$66.64
-69.5%
-55.2%$2.32B$1.11B3.14298News Coverage
RCUS
Arcus Biosciences
2.5714 of 5 stars
$30.93
-2.7%
$62.33
-101.5%
-17.3%$2.17B$77.52M-7.54236
IMAB
I-Mab
1.9781 of 5 stars
$27.18
-6.3%
$91.50
-236.6%
-47.7%$2.12B$236.42M0.002,020
AUPH
Aurinia Pharmaceuticals
2.1305 of 5 stars
$16.40
-4.0%
$32.83
-100.2%
+5.9%$2.11B$50.12M-13.55294Gap Down
TGTX
TG Therapeutics
2.4417 of 5 stars
$14.76
-2.0%
$53.50
-262.5%
-70.7%$2.09B$150K-5.59272Analyst Report
News Coverage
Gap Down
OPK
OPKO Health
1.9064 of 5 stars
$3.01
-7.3%
$6.33
-110.4%
-26.8%$2.05B$1.44B27.375,269Analyst Downgrade
Analyst Revision
News Coverage
EQRX
EQRx
0 of 5 stars
$4.15
-11.1%
N/AN/A$2.02BN/A0.00N/ANews Coverage
Gap Down
NKTR
Nektar Therapeutics
2.2686 of 5 stars
$10.90
-2.6%
$25.83
-137.0%
-32.5%$2.01B$152.91M-4.01718
CORT
Corcept Therapeutics
2.2581 of 5 stars
$17.42
-2.1%
$29.00
-66.5%
-36.6%$2.01B$353.87M20.99236
HRMY
Harmony Biosciences
2.5948 of 5 stars
$34.04
-3.1%
$53.25
-56.4%
-4.0%$1.99B$159.74M170.21150Positive News
CYRX
Cryoport
2.0648 of 5 stars
$42.73
-3.9%
$87.14
-103.9%
-45.9%$1.98B$78.70M-23.87610Gap Down
SDGR
Schrödinger
2.0848 of 5 stars
$27.61
-1.3%
$77.17
-179.5%
-70.8%$1.96B$108.10M-23.80449Analyst Revision
Gap Down
LGND
Ligand Pharmaceuticals
2.3264 of 5 stars
$116.97
-0.6%
$223.75
-91.3%
-17.5%$1.95B$186.42M29.322,018News Coverage
Gap Down
XNCR
Xencor
2.18 of 5 stars
$32.89
-7.0%
$54.78
-66.5%
-27.4%$1.92B$122.69M-328.90202Gap Down
TPTX
Turning Point Therapeutics
1.9442 of 5 stars
$38.08
-3.6%
$124.14
-226.0%
-70.1%$1.88B$25M-9.00142
IRWD
Ironwood Pharmaceuticals
2.2831 of 5 stars
$11.14
-0.5%
$14.50
-30.2%
+8.3%$1.82B$389.52M3.43232
ME
23andMe
1.6098 of 5 stars
$4.40
-4.1%
$11.50
-161.4%
N/A$1.79BN/A0.00572Gap Down
CCXI
ChemoCentryx
2.1331 of 5 stars
$25.34
-1.1%
$75.00
-196.0%
-60.2%$1.77B$64.89M-14.56133Gap Down
TARO
Taro Pharmaceutical Industries
1.9165 of 5 stars
$46.94
-1.9%
$75.00
-59.8%
-40.3%$1.76B$548.97M234.701,417Upcoming Earnings
News Coverage
Gap Up
GBT
Global Blood Therapeutics
2.1402 of 5 stars
$26.83
-3.1%
$68.00
-153.4%
-42.0%$1.73B$123.80M-6.02389
AGIO
Agios Pharmaceuticals
1.8081 of 5 stars
$31.52
-1.1%
$59.00
-87.2%
-34.3%$1.71B$203.20M1.40562
TVTX
Travere Therapeutics
1.5798 of 5 stars
$26.53
-2.3%
$32.40
-22.1%
-6.3%$1.62B$198.32M-5.82262News Coverage
SAVA
Cassava Sciences
1.7064 of 5 stars
$40.12
-1.4%
$146.00
-263.9%
+207.2%$1.61BN/A-72.9411Analyst Report
News Coverage
PRTA
Prothena
2.6498 of 5 stars
$34.31
-3.4%
$67.50
-96.7%
+160.6%$1.60B$850K33.3166
SUPN
Supernus Pharmaceuticals
2.3948 of 5 stars
$29.72
-2.0%
$39.50
-32.9%
-2.7%$1.57B$520.40M19.68563News Coverage
Gap Down
MORF
Morphic
2.3598 of 5 stars
$41.00
-0.4%
$77.67
-89.4%
+32.0%$1.52B$44.94M-15.4189
DVAX
Dynavax Technologies
2.5881 of 5 stars
$12.60
-0.0%
$23.50
-86.5%
+141.4%$1.51B$46.55M-36.00245
BBIO
BridgeBio Pharma
2.5798 of 5 stars
$10.26
-2.1%
$55.29
-438.8%
-84.9%$1.51B$8.25M-2.62391Analyst Revision
Gap Down
VERV
Verve Therapeutics
2.0464 of 5 stars
$30.89
-3.0%
$71.20
-130.5%
N/A$1.49BN/A0.0063
ISEE
IVERIC bio
2.3181 of 5 stars
$12.90
-1.6%
$22.00
-70.5%
+139.0%$1.48BN/A-11.6257
ZGNX
Zogenix
1.8581 of 5 stars
$25.94
-0.0%
$32.10
-23.7%
+34.4%$1.45B$13.64M-5.96218
ERAS
Erasca
1.2132 of 5 stars
$11.86
-4.7%
$25.25
-112.9%
N/A$1.44BN/A0.002,021
PTGX
Protagonist Therapeutics
2.0265 of 5 stars
$28.80
-0.6%
$59.71
-107.3%
+29.6%$1.37B$28.63M-11.9579Gap Down
BCYC
Bicycle Therapeutics
2.2314 of 5 stars
$46.33
-1.3%
$72.88
-57.3%
+75.0%$1.36B$10.39M-16.032,020
XENE
Xenon Pharmaceuticals
2.2998 of 5 stars
$26.29
-3.1%
$44.00
-67.4%
+69.7%$1.36B$32.17M-16.13129Analyst Revision
News Coverage
RXDX
Prometheus Biosciences
2.1448 of 5 stars
$34.77
-0.1%
$42.86
-23.3%
+29.2%$1.35B$1.23M0.0026
AMRX
Amneal Pharmaceuticals
2.5681 of 5 stars
$4.49
-0.9%
$7.88
-75.4%
-10.5%$1.35B$1.99B49.896,000Analyst Upgrade
Analyst Revision
News Coverage
FGEN
FibroGen
1.8131 of 5 stars
$14.43
-0.4%
$29.50
-104.4%
-69.8%$1.34B$176.32M-6.19599
LYEL
Lyell Immunopharma
1.7848 of 5 stars
$5.45
-0.4%
$24.25
-345.0%
N/A$1.30BN/A0.00189News Coverage
NUVB
Nuvation Bio
2.3667 of 5 stars
$5.96
-0.7%
$17.40
-191.9%
N/A$1.30BN/A0.0036
AMRN
Amarin
2.1083 of 5 stars
$3.26
-8.3%
$9.25
-183.7%
-54.4%$1.29B$614.06M84.002,020Analyst Revision
Gap Up
High Trading Volume
MYOV
Myovant Sciences
1.8114 of 5 stars
$13.08
-0.8%
$23.75
-81.6%
-36.8%$1.22B$59.32M-5.01407Upcoming Earnings
Gap Down
AMPH
Amphastar Pharmaceuticals
2.2148 of 5 stars
$24.91
-0.8%
$23.67
-5.0%
+32.2%$1.19B$349.85M34.601,980Gap Down
ENTA
Enanta Pharmaceuticals
2.4681 of 5 stars
$58.59
-0.3%
$90.25
-54.0%
+22.5%$1.19B$97.07M-14.98141
NGM
NGM Biopharmaceuticals
2.3792 of 5 stars
$14.79
-0.1%
$35.00
-136.6%
-48.3%$1.14B$87.37M-9.19210Gap Down
High Trading Volume
ADCT
ADC Therapeutics
1.9514 of 5 stars
$16.11
-4.1%
$45.20
-180.6%
-53.7%$1.11B$2.34M-4.91208
KROS
Keros Therapeutics
2.1665 of 5 stars
$47.30
-1.5%
$86.67
-83.2%
-28.5%$1.11B$10M-17.4535
CDMO
Avid Bioservices
2.4814 of 5 stars
$17.78
-3.3%
$31.67
-78.1%
+28.9%$1.09B$95.87M136.78255Gap Down
IMGN
ImmunoGen
1.8931 of 5 stars
$5.40
-0.9%
$9.50
-75.9%
-26.2%$1.09B$132.30M-15.8879Gap Down
MDGL
Madrigal Pharmaceuticals
2.4514 of 5 stars
$62.83
-0.3%
$177.57
-182.6%
-46.1%$1.07BN/A-4.2942
This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.